Virtual (computed) fractional flow reserve: future role in acute coronary syndromes by Haley, H.A. et al.
This is a repository copy of Virtual (computed) fractional flow reserve: future role in acute 
coronary syndromes.




Haley, H.A., Ghobrial, M., Morris, P.D. et al. (9 more authors) (2021) Virtual (computed) 
fractional flow reserve: future role in acute coronary syndromes. Frontiers in 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
REVIEW
published: 22 October 2021
doi: 10.3389/fcvm.2021.735008
Frontiers in Cardiovascular Medicine | www.frontiersin.org 1 October 2021 | Volume 8 | Article 735008
Edited by:
Angelo Silverio,
University of Salerno, Italy
Reviewed by:
Konstantinos Stathogiannis,
Stanford University, United States
Panagiotis Xaplanteris,





This article was submitted to
Structural Interventional Cardiology,
a section of the journal
Frontiers in Cardiovascular Medicine
Received: 01 July 2021
Accepted: 22 September 2021
Published: 22 October 2021
Citation:
Haley HA, Ghobrial M, Morris PD,
Gosling R, Williams G, Mills MT,
Newman T, Rammohan V,
Pederzani G, Lawford PV, Hose R and
Gunn JP (2021) Virtual (Computed)
Fractional Flow Reserve: Future Role
in Acute Coronary Syndromes.
Front. Cardiovasc. Med. 8:735008.
doi: 10.3389/fcvm.2021.735008
Virtual (Computed) Fractional Flow
Reserve: Future Role in Acute
Coronary Syndromes
Hazel Arfah Haley 1,2,3, Mina Ghobrial 1,2, Paul D. Morris 1,2,3, Rebecca Gosling 1,2,
Gareth Williams 1,2, Mark T. Mills 1,3, Tom Newman 1,3, Vignesh Rammohan 1,2,
Giulia Pederzani 1,2, Patricia V. Lawford 1,2, Rodney Hose 1,2 and Julian P. Gunn 1,2,3*
1Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom, 2 Insigneo
Institute for in silico Medicine, Sheffield, United Kingdom, 3 Sheffield Teaching Hospitals National Health Service Foundation
Trust, Sheffield, United Kingdom
The current management of acute coronary syndromes (ACS) is with an invasive
strategy to guide treatment. However, identifying the lesions which are physiologically
significant can be challenging. Non-invasive imaging is generally not appropriate or
timely in the acute setting, so the decision is generally based upon visual assessment
of the angiogram, supplemented in a small minority by invasive pressure wire studies
using fractional flow reserve (FFR) or related indices. Whilst pressure wire usage is
slowly increasing, it is not feasible in many vessels, patients and situations. Limited
evidence for the use of FFR in non-ST elevation (NSTE) ACS suggests a 25% change
in management, compared with traditional assessment, with a shift from more to less
extensive revascularisation. Virtual (computed) FFR (vFFR), which uses a 3D model of
the coronary arteries constructed from the invasive angiogram, and application of the
physical laws of fluid flow, has the potential to be used more widely in this situation. It
is less invasive, fast and can be integrated into catheter laboratory software. For severe
lesions, or mild disease, it is probably not required, but it could improve the management
of moderate disease in ’real time’ for patients with non-ST elevation acute coronary
syndromes (NSTE-ACS), and in bystander disease in ST elevation myocardial infarction.
Its practicability and impact in the acute setting need to be tested, but the underpinning
science and potential benefits for rapid and streamlined decision-making are enticing.
Keywords: computed blood flow, ACS - ACS/NSTEMI, FFR, vFFR, virtual FFR, angiogram based FFR, coronary
artery modelling
WHAT ARE THE ISSUES WITH CORONARY ANGIOGRAPHY IN
ACS?
The fundamental limitation of CAG is that it is an anatomical, not a physiological, test which reveals
luminal stenoses, with a poor relationship to blood flow and the identification of “significant”
coronary artery disease (1). The severity of an angiographic lesion is typically over-estimated by
eye, and the length under-estimated (2). There is also considerable inter-observer variability in
lesion assessment (3). These weaknesses are only partly addressed by using quantitative coronary
angiography, which has its own limitations (4). In addition, assessment is critically dependent upon
the quality of the angiographic images; inadequate contrast, insufficient projections, overlapping
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vessels, excess movement, and lesions located at ostia, branch
points and in series pose particular challenges. In addition, it
cannot reveal the vulnerability or instability of lesions without
the assistance of intravascular imaging, although this is also a
limitation of physiological assessment (5).
WHAT IS PHYSIOLOGICAL GUIDANCE?
Fractional flow reserve (FFR) is the ratio of the maximum
achievable blood flow in the stenotic coronary artery to






((Pd − Pv) /R)




where Pa is mean aortic (proximal) pressure, Pd is pressure
distal to the stenosis, Pv is the central venous pressure and R is
resistance to flow. FFR approximates to the ratio of the distal
to proximal pressure, so it can be measured with a pressure-
sensitive angioplasty guidewire. FFR is best calculated during
maximum hyperaemia, during which microvascular resistance
(MVR) is assumed minimal or constant which can be achieved
by an infusion of adenosine (see Figure 1).
FFR, or related ’resting’ indices such as resting full
cycle ratio (RFR) or instantaneous wave-free ratio (iFR), is
recommended in arteries with narrowing estimated visually
between 50 and 90%, when non-invasive testing is unavailable
or inconclusive (6). An FFR < 0.80 is the accepted threshold
for ischaemia and justifies intervention. Physiological guidance,
compared with angiography alone, reduces symptom burden,
repeat revascularisation and health expenditure at the time
of percutaneous coronary intervention (PCI) (7–9). A hidden
benefit of physiological guidance is that, perhaps unfortunately,
angiographic precision is not essential.
Abbreviations: AUC, Area under the operator receiving curve; AHA, American
heart association; ACS, Acute coronary syndrome; CABG, Coronary artery bypass
grafting; CAD, Coronary artery disease; CAG, Coronary angiography; CAFFR,
Coronary angiography based FFR; CAAS-vFFR, Cardiovascular angiographic
analysis system for vessel FFR; CCL, Cardiac catheter laboratory; CCS, Chronic
coronary syndrome; CFD, Computational fluid dynamics; CT, Computed
tomography; CTCA, CT coronary angiography; CT-FFR, CT fractional flow
reserve; COMPLETE, Complete revascularisation with multivessel PCI for
myocardial infarction; COMPARE-ACUTE, Fractional flow reserve-guided
multivessel angioplasty in myocardial infarction; DANAMI-3-PRIMULTI,
Complete revascularisation vs. treatment of the culprit lesion only in patients
with ST-segment elevation myocardial infarction and multivessel disease; ESC,
European Society of Cardiology; FAME, Fractional flow reserve vs. angiography
for multivessel evaluation; FFR, Fractional flow reserve; FFRsim, Simplified model
of FFR calculation; FLOWER-MI, Multivessel PCI guided by FFR or angiography
for MI; IFR, Instantaneous wave free ratio; MACE, Major adverse cardiovascular
events; mFFR, Measured fractional flow reserve; MI, Myocardial infarction; MVD,
Multi vessel disease; MVR, Microvascular resistance; NPV, Negative predictive
value; NSTEMI, Non-ST elevation myocardial infarction; NSTE-ACS, Non-ST
elevation acute coronary syndrome; PCI, Percutaneous coronary intervention;
PPV, Positive predictive value; RCT, Randomised control trial; RFR, Resting full
cycle ratio; STEMI, ST elevation myocardial infarction; TIMI, Thrombolysis in
myocardial infarction; vFAI, Virtual functional assessment index; vFFR, Virtual
fractional flow reserve; QALY, Quality adjusted life year; QCA, Quantitative
coronary angiography; QFR, Quantitative flow ratio.
WHAT IS THE EVIDENCE FOR FFR IN
NSTE-ACS?
Whilst the majority of the evidence for FFR is in chronic
coronary syndromes (CCS), there were large NSTE-ACS subsets
in some of the seminal studies. In the FAME study, 30% of
patients had NSTE-ACS. The 2-year rate of major adverse
cardiovascular events (MACE) was significantly reduced in the
FFR- vs. the CAG-guided groups, with no difference between
the CCS and NSTE-ACS cohorts (10). Importantly, the study
also showed that no myocardial infarctions (MI)s occurred in
the FFR-guided deferred lesions in the NSTE-ACS cohort at
2 year follow up (11). A health economic analysis from the
study also revealed that FFR-guided PCI improved outcomes
and costs at 1 year when compared with the CAG-guided
approach (12). In a “real-world” observational study of 3,000
patients with ACS, a lower in-hospital mortality was observed
for FFR guidance than for a CAG-based approach (1.1 vs.
3.1%, p <0.01), and reductions in hospital stay, acute kidney
injury (AKI) and bleeding (13). In a study of 350 ACS patients
randomised to FFR- vs. CAG-guidance, disclosure of the FFR
resulted in changed management in 21.6% of cases, reducing the
number of unnecessary procedures and downstream unplanned
revascularizations (14). A cost-effectiveness assessment disclosed
that increased up-front costs (pressure wire use and laboratory
time) weremore than compensated by later savings in subsequent
hospital stay, events and procedures; and there was also a small
benefit in quality-adjusted life year (QALYs) (15). In another
study of 107 patients with multi-vessel disease and moderate
non-culprit lesions, FFR resulted in 76% of patients not being
revascularised; and importantly there was no MACE in this
group (16). A meta-analysis of the three major RCTs also
concluded that FFR guidance in patients with NSTE-ACS led
to a reduction in the rate of MI without any difference in
death or all-cause mortality and target vessel revascularisation
compared with CAG guided approach (17). In a study of 1,983
patients with ACS (n = 533) and CCS (n = 1,450), FFR led
to a similarly high percentage of reclassification of treatment
in both groups (ACS = 38% vs. CCS = 39%). In the ACS
patients, FFR guidance led to a change from revascularization
in 70% and medical therapy in 30% to revascularisation in
38% and medical therapy in 62%. There was no significant
difference in MACE (8.0 vs. 11.6%; p = 0.20) or symptoms
(92.3 vs. 94.8% angina free; p = 0.25) between the reclassified
(FFR discordant with CAG) vs. the non-reclassified patients
(FFR concordant with CAG) groups. FFR-guided deferral to
medical therapy in the ACS group was as safe as in the CCS
group (MACE 8 vs. 8.5%; revascularization 3.8 vs. 5.9%; and
freedom from angina 93.6 vs. 90.2%). Worse outcomes were
observed in the six percent of patients in whom FFR was
disregarded (18). In a study of 1,596 patients of which 301
had ACS (n = 449 lesions), deferral of the non-culprit lesion
based upon FFR resulted in a MACE 3.8% (ACS) vs. 1.6%
(CCS), mainly driven by ischaemia-driven revascularisation (2.8
vs. 1.1%) (19). Two systematic reviews comparing available data
on FFR guidance confirmed this difference, with no significant
difference in mortality (20, 21). ESC guidelines propose that FFR
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FIGURE 1 | (Left) Right coronary angiogram with moderate stenoses. (Right) Proximal (red) and distal (green) pressure. The FFR is 0.64.
can be used in ACS (class IIb) to assist decision-making in non-
culprit lesions whose severity is moderate (22), which contrasts
with the recommendation to use FFR in intermediate stenoses in
CCS (Class I) for patients with multi-vessel disease (MVD) (class
IIa) (23).
DOES FFR HAVE A ROLE IN STEMI?
FFR has no role in selecting the “culprit” vessel of ST elevation
MI (STEMI), but it may be useful in assessing “bystander”
stenoses. In COMPLETE, a landmark study of 4,041 STEMI
patients with MVD, in which visual, rather than FFR guidance,
was used, complete revascularization reduced the risk of
cardiovascular deaths, MI and repeat revascularizations from
16.9 to 8.7% at 36 months when compared with a culprit-
only-PCI approach; the benefit largely driven by a reduction in
unplanned revascularization (24). In COMPARE-ACUTE (885
patients), DANAMI-3-PRIMULTI (627 patients) and FLOWER-
MI (1,171 patients), an FFR-guided approach, rather than
a purely visual one was used. In COMPARE-ACUTE, the
primary outcome (composite of all-cause mortality, non-fatal
MI, revascularisations and cerebrovascular events) occurred
in 20% of the culprit-only revascularization group vs. 8% in
the FFR-guided complete revascularization group (P < 0.001)
(25). In DANAMI-3-PRIMULTI, the equivalent figures were
22 and 13%, respectively (p = 0.004) (26). The risk of future
cardiovascular events was mainly driven by a 69% reduction
in repeat revascularizations. In contrast, in FLOWER-MI, an
FFR-guided approach in the non-culprit lesions in STEMI was
not found to be superior to an angiography-guided strategy
at reducing the risk of death, MI or repeat revascularization
at 1 year. PCI of non-culprit lesions was performed in 66%
of patients with the FFR-guided strategy and in 97% with the
angiography-guided strategy. The primary outcome occurred in
5.5% (32 of 586 patients) in the FFR-guided approach vs. 4.2%
(24 of 577 patients) in the angiographic-guided group (p = 0.31)
(27). The difference was driven by a non-significant 77% higher
risk of MI in patients assigned to the FFR group (18 patients
in the FFR guided group vs. 10 patients in the angiographic
guided group). The study was powered to detect a 37% lower
risk of the primary composite outcome, but ultimately generated
a wide confidence interval (hazard ratio, 1.32; 95% CI 0.78–
2.23). In addition, intervention on the non-culprit lesions was
encouraged to be performed at index presentation, rather than as
a staged procedure. A larger RCT specifically addressing timing
may be required. A parallel line of enquiry may be necessary
to interrogate the hypothesis that conventional physiological
assessment of bystander lesions may be of lesser importance than
identifying vulnerable plaques.
WHY DO WE USE SO LITTLE PHYSIOLOGY
IN THE ACUTE CARDIAC CATHETER
LABORATORY?
Despite robust evidence supporting the use of FFR, in practise
its use remains low, at <10% of PCIs, and in an even smaller
proportion of diagnostic angiograms; the majority being in
patients with CCS (2, 28). This low uptake in the acute setting
may reflect the time and cost associated with deploying a
pressure wire. Also, if stenting a borderline lesion is likely to be
straightforward, it may be felt that a “quick fix” is reasonable.
This is not, however, a position supported by the evidence. Other
reasons for under-use may include complex anatomy, such as
tortuosity, angulation, calcification and diffuse disease, in which
manipulating a pressure wire might be hazardous. There may
also be a lack of awareness of the accumulating evidence in
ACS confounded by pressure on the operator to make a swift
therapeutic decision in response to situational factors.
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IS FFR RELIABLE IN ACUTE MI?
The validity of FFR in an acuteMI has been questioned due to the
possibility that blunted acute microvascular dysfunction might
limit maximal hyperaemia, reducing the apparent physiological
significance of a lesion (29). Does this mean that the FFR is
“incorrect”? The value is indeed correct and reflects the current
physiology, however the concern is that lesion significance may
increase as the microvasculature recovers. Whilst this may be the
case in a culprit lesion, in a study of 101 patients undergoing
PCI for an acute MI (75 STEMI and 26 NSTEMI), the FFR
measurements in 112 non-culprit vessels did not change between
the acute presentation and follow up (30). In a study of 57 patients
who had recovered from an MI an average 6 days previously,
FFR < 0.75 was associated with sensitivity of 82% and specificity
of 87% vs. SPECT imaging, and the relationship between the
microvascular resistance in the infarcted territory and the viable
myocardium was inversely proportioned (31). Similar results
were found in a separate study of 48 patients (32).
PROBLEMS WITH FFR IN ACS
FFR is based upon the assumption that the relationship between
flow and pressure in healthy and diseased arteries is predictable
from a linear relationship. This is not strictly true, because energy
is lost through friction in the diseased artery (viscous losses), and
there is acceleration of flow at the outlet, producing a curvilinear
relationship, which may particularly affect the acute patient
(33). Also, the microvascular resistance, a crucial influence upon
FFR, may differ between individuals, and be influenced by
clinical, procedural, and extrinsic factors, which may be poorly
controlled in the acute patient (34–36). Prior MI, diabetes,
left ventricular hypertrophy, poorly controlled hypertension,
endothelial dysfunction, and raised central venous pressure or
left ventricular end-diastolic pressure (37) can also contribute.
Uncertainty of the measurement itself is also a feature. The
reproducibility of a therapeutic decision is >95% when the FFR
is outside the 0.75–0.85 range, but only about 50% when it is
close to 0.80 (38). This is of importance in the angiographic
“borderline” lesion, for which the FFR is often also borderline.
Other limitations are the lack of randomised data studying the
use of FFR in left main stem disease, and technical difficulties
measuring ostial, serial and bifurcation lesions (39). Measured
FFR, therefore, has not achieved routine use in the management
of ACS.
WHAT ABOUT CT AND CT-FFR IN ACS?
Functioning as a “triple rule-out,” CT can be used in the
emergency department for patients with chest pain and no
ECG changes to rule out severe coronary disease, acute
aortic syndrome or pulmonary embolism (40). CT coronary
angiography (CTCA) is useful at excluding significant CAD,
with a negative predictive value (NPV) approaching 100% (41).
In a study of 568 patients with suspected ACS, 84% were
identified as low risk, discharged from hospital and had no
adverse cardiac events at 30 days (42). In a study of 368 patients
with chest pain and an inconclusive initial evaluation, CTCA
showed that 50% of patients were free of CAD (43). Current
ESC guidelines recommend CTCA as an alternative to invasive
CAG in patients with low to intermediate risk of CAD and,
when the troponin and ECG are inconclusive, to exclude ACS
as class IIa (44). However, the RAPID-CTCA trial of 1,748
patients did not demonstrate a benefit of CTCA in reducing
death, MI or stent thrombosis in suspected ACS when compared
to standard practise (5.8 vs. 6.1%; p = 0.65) (45). CTCA
is limited at predicting the haemodynamic significance of a
lesion. CT-FFR, however, can demonstrate ischaemia-provoking
lesions by modelling the coronary vasculature and incorporating
computational fluid dynamics (CFD) (46) with a diagnostic
accuracy of 81% (47, 48). CT-FFR is now recommended as an
adjunct to CTCA in stable patients (49). It is limited, however,
by the presence of calcification, tachycardia and arrhythmia (50).
Other limitations are the availability of CT and, for CT-FFR, cost,
FIGURE 2 | Summary of steps for vFFR calculation using the VIRTUheartTM software.
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FIGURE 3 | (A) Processing selected angiogram images. Two views (at least 30 degrees apart) of the LAD are chosen at end diastole (red dot on ECG tracing) from a
patient with NSTE-ACS. (B) The LAD artery is now segmented and ready for a 3D reconstruction prior to CFD simulation. (C) vFFR result after 3D reconstruction and
CFD simulation showing a vFFR in the LAD of 0.74.
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and the requirement for off-site processing (up to 24 h). In the
move towards timely interventional management for the ACS
patient, CTCA is, therefore, generally impractical.
WHAT IS VIRTUAL (V)FFR AND HOW IS IT
PRODUCED?
vFFR is a novel technique to compute FFR non-invasively,
without a pressure wire, using CAG images and CFD. CFD
uses the physical laws of fluid flow, obeying the conservation of
mass, momentum and energy, to simulate blood flow through
a conduit. Several systems have been developed. The first,
VIRTUheartTM, has a high diagnostic accuracy (assessed against
measured FFR) for detecting ischaemic lesions (FFR ≤ 0.80),
with a computing time of <4min (51, 52). The VIRTUheartTM
software was initially validated against mFFR in the VIRTU1
study, which analysed 35 vessels in 19 patients, revealing an
accuracy of 97% (51). In a second study larger study of 101
patients, VIRTUheartTM was found to have an accuracy of 92%
(53). These are similar levels of accuracy compared with other
vFFR systems, although there are no published head-to-head
comparisons. The two key steps in using VIRTUheartTM are
obtaining an accurate 3D model of the diseased coronary artery
and estimating the microvascular resistance. The former requires
a good quality angiogram, with optimal opacification, minimal
magnification, no “panning” and minimal vessel overlap in at
least two orthogonal planes at least 30 degrees apart, ideally with
an ECG trace to identify an end-diastolic frame (54). Accuracy
depends upon not only precise portrayal of the lesion, but
also correct estimation of the MVR. In the absence of a wire
measurement, MVR is estimated by either using a population
average, or some form of personalisation. A typical process is
shown in Figures 2, 3. The VIRTUheartTM system can calculate
the vFFR between any points and diameters, show the percentage
of stenosis and even offer a “virtual stents” (53).
HOW DOES THE DIFFERENT SOFTWARE
FOR CALCULATING VIRTUAL FFR DIFFER
FROM EACH OTHER?
Several systems to calculate vFFR are available. Each has differing
methodology. These include Quantitative Flow Ratio (QFR,
Medis, Leiden, Netherlands and Pulse Medical Imaging, China)
and Cardiovascular Angiographic Analysis System for Vessel
FFR (CAAS-vFFR, Pie medical, Maastricht, Netherlands) based
upon 3D quantitative coronary angiography (QCA); FFRangio
(Cathworks Ltd., Kfar-Saba, Israel) based upon 3D functional
CA mapping with coronary rapid flow analysis; and Virtual
Functional Assessment Index (vFAI) and Simplified Model of
FFR Calculation (FFRsim) based upon 3D QCA and CFD.
VIRTUheartTM is the Sheffield University system, currently
confined to research use. QFR, FFRangio and CAAS-vFFR are
commercially available, with QFR being the first to obtain
CE-mark and FDA approval. Whilst the first QFR study was
based upon CFD, subsequent studies used faster computation
using an algorithm incorporating coefficients from flow data to
calculate pressure drops (55). QFR employs a 3D reconstruction
TABLE 1 | Summarising CA-based FFR software.
Coronary angiography based FFR technique
CA-based FFR
technique














Analytical equations based on laws of
Bernoulli and Poiseuille. Empiric flow
velocity (fQFR), TIMI frame
counting-derived contrast velocity at




≥25 degrees (55, 60, 60–62)
FFRangio Cathworks Ltd.,
Kfar-Saba, Israel








Simple analytical equations based on
Bernoulli and Poiseuille
≥ 2 orthogonal images
for each vessel
≥ 30 degrees (59)
caFFR (FLASH FFR) Rainmed Ltd., Suzhou,
China
CFD based on post angiography TIMI







3D-QCA and steady state CFD ≥2 orthogonal images
for each vessel
≥30 degrees (66)
CA, Coronary angiography; 3D, Three dimensional; QCA, Quantitative coronary angiography; VIRTUheartTM, (University of Sheffield); QFR, Quantitative flow ratio (Medis, Leiden,
Netherlands and Pulse Medical Imaging, China); FFRangio, 3D functional coronary angiography mapping with coronary flow analysis (Cathworks Ltd., Kfar-Saba, Israel); CAAS-
vFFR, Cardiovascular Angiographic Analysis System (Pie medical, Maastricht, The Netherlands); caFFR, Coronary-angiography based FFR (FLASH software); vFAI, Virtual Functional
Assessment Index.
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and a QCA algorithm without reconstructing side branches
(56). The software assumes that the coronary pressure remains
constant in a normal coronary artery and that the distal coronary
flow velocity is similar to the proximal. Based upon the mean
hyperaemic velocities, the software can provide three different
computation values: fixed-QFR (fQFR) based upon a flow
velocity of 0.35 m/s; contrast-QFR (cQFR) applies Thrombolysis
in Myocardial Infarction (TIMI) frame counting analysis at
non-hyperaemic conditions; and adenosine-QFR (aQFR) uses
intravenous administration of adenosine. FFRangio provides
colour-coded vFFR by applying a rapid analysis of flow based
upon Poiseuille’s law. A 3D coronary tree is generated and applies
epipolar ray tracing with mathematical calculation. The software
identifies the stenosis automatically by systematic segment,
branch and junctional analysis. A user correction is required to
correct any axis displacements contributed by movement. The
resistance of the coronary arterial network in each segment is
estimated by the vessel diameter and length, each vessel flow
being based upon the overall impact of the resistance, and
the FFRangio value being calculated as the contribution of each
narrowing to the total resistance and flow (57). CAAS-vFFR
uses 3D model reconstruction, the vFFR being computed by
measuring the pressure drop across a lesion by using simpler
physical laws of viscous resistance and separation loss effects
in coronary flow behaviour (58). In addition, it incorporates
patient’s specific aortic pressure with the assumption that the
velocity of proximal coronary artery is preserved, along with
the maximum hyperaemic blood flow previously determined
from clinical data (59). Table 1 summarises the various CA-based
FFR techniques.
WHAT IS THE EVIDENCE FOR VIRTUAL
CORONARY PHYSIOLOGY IN ACS?
The main clinical hurdle for these virtual systems is to
demonstrate accuracy against measured FFR (mFFR). This is
usually expressed as the new system’s percentage concordance
with the treatment threshold (i.e., FFR> or <0.80). The QFR
system, in a small study of 73 cases, disclosed accuracy of 88.3%
(67) and in a larger study of 308 patients,∼90% (60). vFAI, which
measures the average of the computed pressure ratio between
distal and proximal vessel over a steady state CFD analysis has
an accuracy of 88% (66). The accuracy of FFRangio was 93% in a
small study (63) and 87% in a larger study of 301 patients with
FFR range of 0.75–0.85, which reflects the type of stenosis usually
interrogated in real world setting (57). A sub-analysis from that
study also demonstrated that FFRangio is more accurate than
other established FFR indices like instantaneous wave-free ratio
(IFR) and diastolic hyperaemia-free ratio (DFR) (68). FFRsim, in
a study of 68 vessels, disclosed an accuracy of 96% (69) which
is similar to caFFR (65). The accuracy of CAAS-vFFR is 96%
for vFFR measurements in their pre-defined “grey zone” (0.77–
0.87) (59, 70). This technology also showed good correlation and
accuracy with IVUS confirmed significant LMS disease in 147
patients with CAD (stable and unstable) (71). The accuracy of
these systems vs. FFR in patients with ACS is displayed inTable 2.
WHAT ARE THE ADVANTAGES OF VFFR?
vFFR is fast. Computation time used to be the limiting factor, but
now takes only minutes. The main time-limiting factor is manual
image correction prior to the CFD step. The whole process can
now be done in ’real time’ in the acute CCL while the patient is
on the table. It does not require a pressure wire or pharmacologic
hyperaemia. In addition, the 3D anatomical model can assist with
treatment planning, selection of stent size and ’virtual coronary
intervention’ together with an estimate of post-stent FFR (53,
63, 73). The same modelling technique can also predict the local
haemodynamic consequence of a particular stenting strategy
(74). Deploying vFFR does not supplant measured (m)FFR; if
a lesion is equivocal at both angiography and vFFR, a pressure
wire can still provide ultimate accuracy. There are, though, a few
situations in which vFFR might actually be superior to mFFR.
The first is serial lesions. Although a pressure wire “pullback” can
provide some clues as to the relative significance of serial lesions,
it is not infallible. In contrast, vFFR can reveal the FFR at each
lesion simply by excluding the other lesion and modelling the
lesion in question as if the other were not present. Of course,
it can also model both together too. The second situation is
when lesion complexity would make passing a pressure wire
undesirable or hazardous. Another advantage is that vFFR can
be used in any CCL without interventional capability. Also, the
cost on a per-patient basis is likely to be low, because the business
model for most commercially available systems is based upon an
institutional licence.
DOES VFFR HAVE ANY LIMITATIONS?
Whilst the final coloured image appears seductive, its validity
is mainly dependent upon good angiographic images, which
require meticulous technique. Lesions at ostia, and at or close
to the left main or a bifurcation, are difficult to model. In
practise, in most CCLs, the radiographer is the most suitable
professional to run the software but, even so, thorough training
and practise is important. Casual users are considerably less
accurate and consistent than regular users, largely due to errors
in the 3D reconstruction; expert re-analysis of their models
revealing errors that can lead to a change in the treatment
decision in 37% cases (75). Although up to 50% of “standard”
angiograms are unsuitable for processing, with a few simple
improvements this proportion can be increased to 80% (76).
This limitation is unfortunate, because it is the antithesis of
measured FFR, where a scrupulous angiogram is less important.
In addition, the distal outlet boundary condition is proximal to
the CMV circulation, and a fundamental assumption of CMV
function (maximal dilatation) is made to compute pressure
from flow. The degree of CMV response to hyperaemia varies
from person to person, which is why personalisation of this
parameter is so important in vFFR. Also, very severe stenoses
are difficult to model because the width of the lumen is less than
a pixel, although in practise the likelihood is that such a lesion
is physiologically significant. Finally, physiological measurement
of all kinds is of most use in the assessment of angiographically
intermediate lesions. So, however small the error on a vFFR





















TABLE 2 | Summarising the evidence of vFFR in ACS.
Summary of angiography based virtual FFR trials involving patients with ACS














PPV (%) NPV (%) AUC (%)
Li et al. (65) caFFR Prospective,
multi-centre, single-arm
study
4.5 ± 1.5 328 275 - 275 95.7 0.89 ±0.10 90.4 98.6 97.2 95 0.98
Tröbs et al.
(72)
























n/a 100 40 26 14 n/a 0.89 ±0.07 97 74 85 89 0.93
Tu et al. (55) QFR Prospective
observational study
<10 68 9 - 9 88 0.81 ±0.11 78 93 82 91 0.93
Xu et al. (60) QFR Prospective,
multi-centre,
observational study












n/a 436 123 18 105 93.4 0.82 ±0.08 75 97.8 89.3 94.2 0.86
Papafaklis
et al. (66)
vFAI Retrospective study n/a 120 41 8 33 90.4 0.78 ±0.18 86.2 87.8 79.9 93.8 91.9
*Not specified; n/a, not reported; BA, Bland-Altman; Sen, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiver operating curve; caFFR, Coronary-angiography based
FFR (FLASH software); FFRangio, 3D functional coronary angiography mapping with coronary flow analysis (Cathworks Ltd., Kfar-Saba, Israel); CAAS-vFFR, Cardiovascular Angiographic Analysis System (Pie medical, Maastricht, The
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FIGURE 4 | (A) Example of vFFR application in STEMI. (a–c) A case of anterior STEMI: (a) occluded proximal LAD; (b) mid RCA non-culprit stenosis; and (c) vFFR
model of the RCA lesion. (d–f) A case of infero-lateral STEMI: (d) occluded mid Cx; (e) non-culprit mid-LAD stenosis; and (f) vFFR model of the mid LAD lesion. (B)
vFFR use in NSTE-ACS; case 1. (a) Severe RCA stenosis, judged to be the “culprit,” and not requiring vFFR; (b) mid-LAD stenosis; (c) stenosis in the marginal branch
(d) vFFR model of the LAD lesion; and (e) vFFR model of the marginal lesion. (C) vFFR use in NSTE-ACS; case 2. (a) Probable culprit LAD stenosis; (b) Probable
bystander ostial diagonal stenosis; (c) vFFR model of the LAD lesion; (d) vFFR model of the D1 lesion.
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FIGURE 5 | Proposed algorithm for the use of vFFR in the management of patients with ACS.
system is, and it is usually at least±0.10, if the vFFR is calculated
to be 0.75–0.85, doubt will remain, and a measured value may
be required. There is a further uncertainty, which also applies to
measured FFR, which is that the physiological significance of a
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lesion, particularly in the acute patient, may not correlate with
the presence of vulnerable plaque (77–79), probably explaining
why long term outcomes are worse in ACS compared with CCS,
even with physiological guidance. vFFR, therefore, whilst being
an improvement over current management, is unlikely to provide
a complete treatment strategy.
POTENTIAL APPLICATION OF VFFR IN
ACS
Amajor attraction of vFFR for patients with ACS is that it can be
used at the time of invasive management in a “one-stop shop,”
in which coronary anatomy can be revealed alongside lesion-
specific ischaemia testing. This is both time- and cost- efficient.
It could be particularly useful in the common situation of multi-
vessel, multi-lesion disease, when the culprit is frequently not
angiographically obvious. Limited data support intervention for
non-culprit lesions (14, 24–26) but, in the “real world” and,
FFR guidance being rarely used (80), vFFR would provide an
opportunity to select lesions requiring intervention without
instrumentation and, perhaps more importantly, eliminating
those that do not. This may be particularly important in apparent
triple vessel disease, in which bypass surgery could be avoided.
The greatest advantage is that vFFR could bring the advantage
of coronary physiology to many more patients with ACS than
at present. Finally, recent CFD-based modelling innovations
are able to predict microvascular resistance which is known to
be of prognostic significance in ACS (81). Examples of vFFR
application in patients with ACS are shown in Figure 4.
HOW SHOULD VFFR BE USED IN THE
ACUTE CARDIAC CATHETER
LABORATORY?
A potential algorithm for the invasive management of ACS,
incorporating vFFR, is shown in Figure 5.
THE INTEGRATION OF VFFR INTO
STANDARD MANAGEMENT OF ACS
Three approaches are possible. The first is simply to assume
that the benefits seen in the trials of measured FFR are
directly transferrable to vFFR and employ vFFR routinely.
However, in the light of the limitations of vFFR outlined
here, this assumption may be optimistic. The second would
be to interrogate existing data derived from studies employing
angiographic guidance, generating post-hoc vFFRs, and re-
evaluating outcomes in accordance with vFFR. Because vFFR
requires optimal angiographic images, however, many cases
would be excluded using this approach; and it would be subject
to the limitations of retrospective studies. The third would be
to undertake prospective, randomised, controlled trials of vFFR-
vs. CAG- guidance with clinical and health economic endpoints.
A multi-centre RCT of 3,860 patients is currently investigating
the superiority and efficacy of QFR- vs. CAG-guidance (82).
Ultimately, endorsement in clinical guidelines will be required.
Whichever approach is adopted, this technology is here to stay.
LEARNING POINTS
1. Measured FFR is under-used for cost and logistic reasons.
2. Virtual (computed) FFR (vFFR) can be constructed from a
coronary angiogram and does not need a pressure wire.
3. vFFR can be applied to intermediate lesions in ACS patients.
4. It can provide treatment guidance while the patient is in the
cardiac catheter laboratory.
5. vFFR requires meticulous coronary angiography.
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